Skandinaviska Enskilda Banken AB publ Cuts Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Skandinaviska Enskilda Banken AB publ trimmed its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.0% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 186,001 shares of the medical equipment provider’s stock after selling 1,938 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned 0.05% of Intuitive Surgical worth $82,770,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. One Wealth Management Investment & Advisory Services LLC increased its position in shares of Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock valued at $310,000 after acquiring an additional 23 shares during the period. Indiana Trust & Investment Management CO increased its stake in shares of Intuitive Surgical by 5.3% during the second quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after buying an additional 25 shares during the period. Hoxton Planning & Management LLC lifted its stake in Intuitive Surgical by 4.9% in the second quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock worth $238,000 after acquiring an additional 25 shares during the period. First Affirmative Financial Network grew its holdings in shares of Intuitive Surgical by 2.7% during the 2nd quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock worth $443,000 after acquiring an additional 26 shares during the period. Finally, Moors & Cabot Inc. raised its position in shares of Intuitive Surgical by 2.3% in the 2nd quarter. Moors & Cabot Inc. now owns 1,159 shares of the medical equipment provider’s stock worth $516,000 after acquiring an additional 26 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Robert Desantis sold 188 shares of the stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $482.21, for a total value of $90,655.48. Following the sale, the executive vice president now owns 5,506 shares in the company, valued at $2,655,048.26. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Intuitive Surgical news, EVP Myriam Curet sold 2,818 shares of Intuitive Surgical stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the completion of the sale, the executive vice president now directly owns 298 shares of the company’s stock, valued at approximately $136,522.74. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Robert Desantis sold 188 shares of the stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $482.21, for a total value of $90,655.48. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,655,048.26. The disclosure for this sale can be found here. Insiders sold a total of 53,120 shares of company stock valued at $25,528,753 over the last 90 days. Insiders own 0.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. JPMorgan Chase & Co. boosted their price target on Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Morgan Stanley lifted their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Truist Financial increased their price target on shares of Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. The Goldman Sachs Group began coverage on shares of Intuitive Surgical in a report on Thursday, May 30th. They issued a “buy” rating and a $500.00 price objective for the company. Finally, Stifel Nicolaus increased their target price on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research note on Friday, July 19th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Price Performance

NASDAQ:ISRG opened at $490.01 on Friday. The company has a market cap of $173.81 billion, a price-to-earnings ratio of 88.45, a PEG ratio of 5.41 and a beta of 1.39. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $496.18. The stock’s 50 day simple moving average is $467.17 and its two-hundred day simple moving average is $424.26.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter last year, the firm earned $1.18 EPS. The firm’s revenue for the quarter was up 14.5% compared to the same quarter last year. As a group, analysts anticipate that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.